SUA

SIGTRAN Protocol Testing and Emulation Suite

Retrieved on: 
Thursday, December 14, 2023
Transfer, MAP, TCAP, GMSC, TDM, Network switching subsystem, M3UA, RNC, Service, SCCP, ICMP, SMSC, BICC, GGSN, UMTS, Mobile Application Part, ISDN, MTP, MNC, SSF, TUP, ISUP, Human, SGSN, IP, GPRS, SIGTRAN, MGC, SS7, GMLC, Software-defined networking, SCTP, GUI, IUA, IMSI, CAP, EIR, INAP, TMSI, MCC, SCF, MSC, SUA, Internet, HLR, CCBS, ITU, Bearer, PRI, ANSI, Analyser, GSM, MSIN

From small-scale deployments to large and complex networks, our SIGTRAN Protocol Test Solutions scales seamlessly, offering consistent performance across varied scenarios.

Key Points: 
  • From small-scale deployments to large and complex networks, our SIGTRAN Protocol Test Solutions scales seamlessly, offering consistent performance across varied scenarios.
  • It supports the same application and call management functions as SS7 but uses two protocol layers on top of Internet Protocol (IP): Stream Control Transport Protocol (SCTP) and M3UA MTP3 User Adaptation Layer.
  • GL's SIGTRAN Protocol Test Suite includes:
    GL's multi-protocol emulation test suite Message Automation and Protocol Simulation (MAPS™) SIGTRAN is an advanced protocol emulator designed for emulating SS7 over IP Networks.
  • NetSurveyorWeb™ is a web-based dashboard with back-end database that connects to a SIGTRAN protocol analyzer probe, enabling the monitoring of the entire SIGTRAN network.

Latest Updates of Viva's Portfolio Companies

Retrieved on: 
Monday, December 4, 2023
JAK1, NMPA, Patient, American College of Rheumatology, Bayer, SUA, Neoplasm, Cataract, Therapy, URAT1, MBA, Cancer, Health care, Inflammation, Fabry disease, Safety, Toxicity, IND, SHP2, USD, Strong, Letter, Woman, EA Phenomic, Pharmacokinetics, VBI, HER2, MPM, Antibody, GCS, GEJ, Boehringer, Research, Plasma, Boehringer Ingelheim, Clinical trial, Investment, MaRS Discovery District, FDA, American College, Phase II, Clostridial necrotizing enteritis, Selective, MPH, ACR, EGFR, Pharmaceutical industry, Astellas Pharma, Phase, Deka, Facet joint arthrosis

TORONTO & WALTHAM, Mass.--(BUSINESS WIRE)--On Nov. 29th, Phenomic AI ("Phenomic"), invested and incubated by Viva BioInnovator (VBI), announced that they have entered into a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers. The partners will leverage Phenomic's expertise in target identification and stromal biology based on its scTx® single-cell transcriptomics platform which will greatly enhance Boehringer's efforts to develop first-in-class medicines to transform the lives of people with cancer by delivering meaningful advances with the ultimate goal to cure a range of cancers. Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones. Phenomic is also eligible to receive more than USD $500 million in licensing fees as well as clinical, regulatory and commercial milestones in addition to royalties on future product sales.

Key Points: 
  • HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development.
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva's portfolio companies have new updates.
  • Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones.

Atom Bioscience Raises $83M in a D-Round Financing to Support Global Pivotal Clinical Trials of ABP-671, a New Treatment for Chronic Gout

Retrieved on: 
Monday, October 16, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Incidence, Probability, Urine, Mass balance, Inflammation, Gout, Aes, Benzbromarone, Liver, Kidney failure, IND, Safety, SUA, Disease, Atom, DSM-IV codes, Chugai Pharmaceutical Co., CNY, Hyperuricemia, URAT1, Patient, Quality of life, Pharmaceutical industry, Dietary supplement

After this round of financing, Atom has raised a total of nearly $165 million.

Key Points: 
  • After this round of financing, Atom has raised a total of nearly $165 million.
  • "We appreciate the support of every investment institution involved in the D-round financing and previous investors,” said Dr. William Dongfang Shi, CEO, Chairman and Founder of Atom Bioscience.
  • Maintaining sUA levels of 5 mg/dL to 4 mg/dL in gout patients is recommended by many national gout treatment guidelines.
  • At these levels gout tophi are re-dissolved, tophi size and quantity are reduced and eventually acute gout attacks are reduced.

Atom Bioscience Doses First Patient in Phase 2b/3 Clinical Trial of a New Treatment for Chronic Gout

Retrieved on: 
Monday, October 9, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, SUA, Probability, Urine, DSM-IV codes, Liver, Kidney failure, Chugai Pharmaceutical Co., Safety, Inflammatory arthritis, Hyperuricemia, URAT1, Gout, Patient, Part, Pharmaceutical industry

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the first patient has been dosed in a Phase 2b/3 clinical trial of ABP-671, a novel orally administered URAT1 inhibitor, for the treatment of chronic gout.

Key Points: 
  • Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the first patient has been dosed in a Phase 2b/3 clinical trial of ABP-671, a novel orally administered URAT1 inhibitor, for the treatment of chronic gout.
  • Part 2 of the study will be a confirmatory study for dosing regimens of ABP-671 selected from Part 1.
  • “Gout affects more than 50 million people worldwide and is on the rise in many countries,” said Atom Bioscience CEO, Chairman and Founder Dr. William Dongfang Shi.
  • At these levels gout tophi are re-dissolved, tophi size and quantity are reduced and eventually acute gout attacks are reduced.

AI startup Carenostics raises $5 million in Seed funding led by M13 to transform healthcare through earlier diagnosis and treatment of chronic disease patients

Retrieved on: 
Thursday, September 14, 2023
Natural language processing, SUA, Asthma, EU, Hackensack Meridian Health, Chronic kidney disease, Health, Disability, Artificial intelligence in healthcare, Association of British HealthTech Industries, Internal medicine, Journal of General Internal Medicine, Mass General Brigham, General partnership, Hackensack, Cerner, MIT, Electronic health record, McKinsey & Company, NLP, Doctor of Philosophy, Hospital, Journal, Patient, EHR, Physician, M13, Healthcare in the United States, Diagnosis, Entrepreneurship, CIO, KPMG, Death, CKD, Computer science, Conditional sentence, Copper, Pharmaceutical industry, Medical device, Nursing, Management, Kanishka, Humana, Amazon, AI

NEW YORK, Sept. 14, 2023 /PRNewswire-PRWeb/ -- Carenostics, a pioneering healthcare AI startup tackling undiagnosed and undertreated chronic disease, has successfully closed a $5 million seed funding round led by M13. Other participants in the round include Greatpoint Ventures, Gaingels, and Kurt Hillzinger, Chairman of Humana, who also joined Carenostics' advisory board.

Key Points: 
  • NEW YORK, Sept. 14, 2023 /PRNewswire-PRWeb/ -- Carenostics, a pioneering healthcare AI startup tackling undiagnosed and undertreated chronic disease, has successfully closed a $5 million seed funding round led by M13.
  • Carenostics, a pioneering healthcare AI startup tackling undiagnosed and undertreated chronic disease, has successfully closed a $5 million seed funding round led by M13.
  • Carenostics has developed a revolutionary AI platform that identifies undiagnosed and undertreated chronic disease patients and prompts clinicians within their current workflows to intervene earlier.
  • He holds a PhD in AI, and previously led Healthcare AI for Siemens and KPMG's US Healthcare & Life Sciences AI & Analytics practice.

Latest Updates of 7 Viva's Portfolio Companies

Retrieved on: 
Friday, July 28, 2023
Dai, FALCON, Head, Acquisition, Patient, Fabry disease, SUA, Tissue, Pharma, Gout, Therapy, Heart failure, CSO, GABAA receptor negative allosteric modulator, Research, NAM, VBI, Small RNA, Medicine, Liver, Growth, CIO, Listeria monocytogenes non-coding RNA, Phase, FDA, URAT1, G protein-coupled receptor, SRT, PAR2, DSM-IV codes, Gq alpha subunit, Glaucoma, Ocular hypertension, SAN, Mercury (element), Allosteric regulation, IOP, Flare, Central nervous system, Drug development, Quality of life, Facet joint arthrosis, RNA, Novartis, Cardiology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Fine chemical, Riparian zone, Domain, Pfizer

WATERTOWN, Mass.-- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases. Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.

Key Points: 
  • WATERTOWN, Mass.-- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases.
  • Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.
  • In exchange for exclusive rights to a Riparian preclinical program, Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics.
  • DTx Pharma utilizes its groundbreaking FALCON™ platform, a conjugated oligonucleotide technology using fatty acid ligands, to tackle the delivery challenges of oligonucleotide therapies.

Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States

Retrieved on: 
Thursday, June 29, 2023
Pharmacodynamics, SUA, PK, Fortress Biotech, Gout, Dotinurad, Pharmacokinetics, Patient, Therapy, Safety, Pharmaceutical industry, Hyperuricemia

MIAMI, June 29, 2023 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia, today announced topline data from the Phase 1 clinical trial evaluating dotinurad in healthy volunteers in the United States (“U.S.”).

Key Points: 
  • The randomized, placebo-controlled Phase 1 clinical trial evaluated the safety, tolerability, pharmacokinetics (“PK”) and pharmacodynamics (“PD”) of multiple doses of dotinurad in U.S. healthy subjects.
  • Dotinurad was shown to be safe and well tolerated with no severe adverse events observed at any dose level.
  • Pharmacodynamic data from the Phase 1 trial were also comparable to the Japanese data where over 1,000 subjects were exposed to dotinurad, including rapid and significant serum uric acid (“sUA”) reduction.
  • We are initiating a Phase 1b clinical trial in gout patients in the U.S. this summer and expect to begin pivotal clinical trials in 2024.”

Atom Bioscience Announces Positive Results of Phase 2a China Clinical Trial of Its URAT1 Inhibitor for Chronic Gout

Retrieved on: 
Wednesday, March 1, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Gout, American College, Safety, Society, European Alliance of Associations for Rheumatology, URAT1, European Alliance, Chugai Pharmaceutical Co., Risk, Sudden death, Hepatotoxicity, Patient, American College of Rheumatology, Hyperuricemia, Therapy, Uric acid, Nephrotoxicity, SUA, Urine, DSM-IV codes, Pharmaceutical industry, Dietary supplement, Rheumatology

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing best in class treatments for inflammatory and metabolic diseases, announced today positive results from its China Phase 2a clinical trial of ABP-671.

Key Points: 
  • Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing best in class treatments for inflammatory and metabolic diseases, announced today positive results from its China Phase 2a clinical trial of ABP-671.
  • The randomized, double-blind, placebo-controlled trial enrolled 54 patients with gout or hyperuricemia across six cohorts, with 7 randomized to ABP-671 and 2 to placebo per cohort.
  • At a dose of 1 mg ABP-671 once daily (QD), 86% of patients reached serum uric acid (sUA) levels below 6 mg/dL.
  • The Phase 2a Australian study met its primary objective of lowering sUA levels to below 6 mg/dL and was well tolerated.

ARTHROSI ANNOUNCES POSITIVE TOPLINE RESULTS FOR AR882 PHASE 2B STUDY

Retrieved on: 
Thursday, January 5, 2023
American College, Arthritis, Therapy, ACR, Gout, SAN, SUA, American College of Rheumatology, Patient, Cardiovascular disease, Classification, Degenerative disease, Hypertension, European Alliance, EULAR, Hyperlipidemia, Chronic kidney disease, Diabetes, Liver disease, Pharmaceutical industry, Rheumatology

SAN DIEGO, Jan. 5, 2023 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company, today announced positive topline results from its Phase 2b clinical study of AR882 for the treatment of chronic gout, providing a strong foundation to advance into Phase 3 clinical development.

Key Points: 
  • SAN DIEGO, Jan. 5, 2023 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company, today announced positive topline results from its Phase 2b clinical study of AR882 for the treatment of chronic gout, providing a strong foundation to advance into Phase 3 clinical development.
  • The Phase 2b study was a global, multicenter, 12-week, randomized, double-blind, placebo-controlled study of 140 gout patients who met the gout classification according to the American College of Rheumatology (ACR) and The European Alliance of Associations for Rheumatology (EULAR).
  • In the study, patients received a daily dose of 50 mg AR882, 75 mg AR882, or matching placebo.
  • "We are delighted to share the positive results from our Phase 2b study and are looking forward to meeting with the regulatory agencies to align on a strategy for the Phase 3 clinical development plans," said Arthrosi CEO Litain Yeh.

From the Tax Law Offices of David W. Klasing - Can You Be Charged with Money Laundering and Tax Evasion at the Same Time?

Retrieved on: 
Wednesday, November 30, 2022
Offense, Deception, Revenue stream, Multimedia, Knowledge, Tax law, CPAS, Government, Racketeer Influenced and Corrupt Organizations Act, RICO, Laundering, Internal Revenue Service, Tax, Dodge, SUA, Federation, Loss of rights due to conviction for criminal offense, Southampton, Fraud, Crime, Cryptocurrency, Office supplies

If you face tax evasion and money laundering charges, you will be confronted with a whole host of life altering legal consequences.

Key Points: 
  • If you face tax evasion and money laundering charges, you will be confronted with a whole host of life altering legal consequences.
  • The crimes of tax evasion and money laundering do not necessarily have to be done together.
  • It is very possible that a defendant charged with money laundering could also be charged with tax evasion.
  • SOURCE Tax Law Offices of David W. Klasing, PC
    View original content to download multimedia: https://www.prnewswire.com/news-releases/from-the-tax-law-offices-of-dav...
    SOURCE Tax Law Offices of David W. Klasing, PC